Ron Vender, MD, is a dermatologist in Hamilton, Ontario, and is the founder and director of Dermatrials Research Incorporated and Venderm Consulting Inc. He is also an associate clinical professor at McMaster University in the Department of Medicine, Division of Dermatology.

3-Year Patient-Reported Psoriasis Outcomes for Bimekizumab, With Ron Vender, MD

 emphasizing that its design reflects the types of patients dermatologists see in everyday clinical practice.

In this interview, Vender noted that the study’s head-to-head comparison of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, with secukinumab, an established IL-17A inhibitor, provides meaningful informtion beyond traditional efficacy endpoints.

“This paper in particular was looking at patient reported outcomes in that and not necessarily efficacy in terms of [body surface area] or [Psoriasis Area and Severity Index], but we, of course, we did look at that as well,” Vender explained.

While PASI and body surface area (BSA) outcomes remain important, Vender stressed that the most compelling aspect of this analysis was its focus on patient-reported outcomes (PROs). According to Vender, rapid relief of symptoms is critical in psoriasis management. He pointed to data showing improvements in itch, skin pain, and scaling as early as the 4-week mark with bimekizumab use.

Vender underscored early attainment of PASI 0 alongside a Dermatology Life Quality Index (DLQI) score of 0 or 1 reflects not just clearance of skin, but meaningful quality-of-life improvement. At a single year and extending through 3 years, Vender emphasized the durability of patients’ responses. He acknowledged clinicians often express concern about loss of efficacy over time with biologic therapies, but the sustained symptom resolution and maintained low DLQI scores observed with continued bimekizumab therapy address that concern.

Importantly, he also discussed the subgroup of patients who switched from secukinumab to bimekizumab during the open-label extension. These patients experienced additional improvements after switching, suggesting that dual IL-17A/F inhibition may provide incremental benefit for certain individuals. However, Vender was careful to note that secukinumab remains an effective and widely used therapy; the findings represent comparative gains rather than shortcomings.

Overall, Vender framed the data as reinforcing the importance of considering both rapidity and durability of patient-centered outcomes when selecting biologic therapy for moderate to severe plaque psoriasis.

The quotes used in this summary were edited for clarity.

Vender reported support from AbbVie, Alumis, Amgen, Arcutis, Bausch, Bristol Myers Squibb, Celltrion, JAMP, Janssen, Leo, Lilly, Meiji, Novartis, Organon, Orka, Sandoz, Sun, Takeda, and UCB.

Augustin M, Feldman SR, Warren RB, et al. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. JAMA Dermatol. Published online February 18, 2026. 

Smith T. BE RADIANT Trial: Bimekizumab Effective for Psoriasis After 3 Years of Use. HCPLive. February 19, 2026. Accessed February 20, 2026. 

https://www.hcplive.com/view/be-radiant-trial-bimekizumab-effective-psoriasis-after-3-years-use

Videos

This interview with Vender highlights recent findings on patient-reported outcomes (PROs) in patients in the BE RADIANT trial with psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Real-World Upadacitinib Results in Ulcerative Colitis

New interim data from the ongoing PROFUNDUS study, presented at the European Crohn’s and Colitis Organisation Congress, provide important real-world insight into the effectiveness and safety of upadacitinib (Rinvoq) in patients with moderate-to-severe ulcerative colitis (UC).

While randomized controlled trials established the drug’s efficacy under tightly controlled conditions, the PROFUNDUS findings help clarify how those results translate into everyday clinical practice.

, Remo Panaccione, MD, director of the inflammatory bowel disease unit at the University of Calgary, explained that randomized controlled trials rely on strict inclusion and exclusion criteria, often excluding the complex patients physicians routinely encounter. Real-world studies like PROFUNDUS, by contrast, include patients with diverse comorbidities, varied steroid tapering approaches, and heterogeneous prior treatment histories.

“When we complement those findings from the randomized controlled trials with real world evidence, if we see that the response rates and remission rates that we're seeing in the clinical trials hold up in the real world in these complex settings, it gives us a lot more confidence that the trial results are valid and that they can be translated into our clinical practice,” Panaccione explained. “Plus, it gives us that experience in those patients that are not necessarily included in the clinical trials.”

The interim analysis evaluated 494 of the first 500 eligible adult patients (aged 18-79 years) with moderate-to-severe UC who initiated once-daily upadacitinib across 16 countries, per investigator discretion and according to the local label. Induction was initiated with the first dose of upadacitinib 45 mg at the beginning of the study. Maintenance was initiated with the start of upadacitinib 15 mg or upadacitinib 30 mg after completion of the induction phase.

Assessed endpoints included clinical response per Partial Adapted Mayo Score (PAMS), corticosteroid (CS)-free response per PAMS, clinical remission per Partial Mayo Score (PMS), absence of abdominal pain, and absence of bowel urgency at week 26.

Among the overall population at week 26, with any upadacitinib dose, 81.8% of patients achieved clinical response, 72.4% clinical remission, 66.3% no abdominal pain, and 71.9% no bowel urgency. Among those on baseline CS, 64.4% attained CS-free response. Of note, similar results were observed for all endpoints, regardless of advanced therapy status.

Among patients treated with upadacitinib induction/maintenance) at either 45/15 mg, 45/30 mg, or any upadacitinib dose, adverse event (AE) were 66.0%, 50.8%, and 51.4%, respectively. Serious AEs were 3.8%, 4.6%, and 5.7%, and severe AEs were 5.7%, 4.0%, and 5.5%. Within the subgroup of patients who experienced TEAEs potentially related to upadacitinib, as assessed by the study investigator, exhibited serious and severe AEs at 3.6%, 6.3%, 6.9%, and 7.1%, 5.4%, 6.9%, respectively.

Panaccione called attention to the consistency of the results across advanced therapy–naïve and experienced populations. Of note, in October 2025, the US Food and Drug Administration approved an updated indication statement for upadacitinib for the treatment of adults with moderately to severely active UC and moderately to severely active Crohn's disease (CD), allowing the use of upadacitinib for patients with moderately to severely active UC or CD after they have received ≥ 1 approved systemic therapy in the event tumor necrosis factor (TNF) blockers are clinically inadvisable. Previously upadacitinib was only indicated for adults who had an inadequate response or intolerance to ≥ 1 blockers.

“This data from the real world studies allows physicians to feel very confident that they can position upadacidinib in different patient populations,” Panaccione said.

Editors’ Note: Panaccione reports relevant disclosures with Abbott, AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Janssen, Lilly, Novartis, Takeda, and others.

R Panaccione, M Fumery, D Bettenworth, S Danese, P Morisset, M Mallick, S H Chen, J Kim, S Suravaram, G Parkes, P1073 Real-World Effectiveness, Symptomatic Improvement, and Safety of Upadacitinib in Patients With Moderate-to-Severe Ulcerative Colitis: Interim Findings From the PROFUNDUS Study, 

, Volume 20, Issue Supplement_1, January 2026, jjaf231.1254, 

https://doi.org/10.1093/ecco-jcc/jjaf231.1254

Brooks A. FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD. HCPLive. October 13, 2025. Accessed February 20, 2026. 

https://www.hcplive.com/view/fda-approves-updated-indication-for-upadacitinib-rinvoq-in-ibd

Panaccione recaps interim PROFUNDUS data showing real-world efficacy and safety of upadacitinib (Rinvoq) for ulcerative colitis.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

PROFUNDUS: Real-World Outcomes With Upadacitinib in Ulcerative Colitis, With Remo Panaccione, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A randomized, placebo-controlled phase 2a trial evaluating SPL026, an intravenous formulation of dimethyltryptamine (DMT), met its primary endpoint in adults with moderate-to-severe 

, demonstrating a statistically significant reduction in depressive symptoms at 2 weeks compared with placebo. The findings represent one of the first controlled trials of a short-acting psychedelic in MDD.

 SPL026 (intravenous dimethyltryptamine, DMT)

 Short-acting serotonergic agonist; 5-HT2A receptor agonist

 Moderate-to-severe major depressive disorder

 –7.35 MADRS point difference vs placebo at Week 2 (

 (≥50% MADRS reduction at Week 2): 35% vs 12%

 No treatment-related serious adverse events reported

 SPL026 not advancing; informing HLP004 Phase 2 GAD program

“We have shown that a single dose of SPL026 is safe, effective and durable, with treatment effects comparable to other promising interventional treatments often requiring much longer treatment sessions,” lead investigator David Erritzoe, MD, PhD, from Imperial’s Department of Brain Sciences, said in a statement, “Although such early trial results should always be interpreted with some caution, these data show the promise of DMT as a potentially more cost-effective treatment for clinical depression than related serotonergic agonists with longer psychoactive action due to the shorter dosing sessions.”

SPL026 is an intravenous formulation of DMT, a short-acting serotonergic psychedelic that acts primarily as a 5-HT2A receptor agonist. Unlike psilocybin, which typically produces psychoactive effects lasting 4 to 6 hours, intravenous DMT has a substantially shorter duration of acute subjective effects, often less than 30 minutes.

In the double-blind stage of the study, a single 21.5-mg intravenous infusion of SPL026 administered over 10 minutes resulted in a mean difference of –7.35 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 2 compared with placebo (95% CI, –13.62 to –1.08; 

=.023). Treatment effects were detectable as early as week 1, with a mean difference of –10.75 points (95% CI, –16.95 to –4.55; 

 =.002). Response rates, defined as ≥5 0% reduction in MADRS score at week 2, were 35% in the SPL026 arm versus 12% with placebo. Remission rates (MADRS ≤ 10) were 29% vs12%, respectively.

The study enrolled 34 participants (mean age 32.8 years; 29.4% female; predominantly White) with a mean depression duration of 10.5 years. Participants were randomized 1:1 to receive SPL026 (n = 17) or placebo (n = 17) in conjunction with supportive psychotherapy that included preparation and integration sessions. The primary endpoint was the change in MADRS score from baseline to week 2.

In an open-label extension, all participants were eligible to receive SPL026 2 weeks after the initial dose, with antidepressant effects reported as persisting up to 3 months post–first dose. Some participants reportedly maintained benefits up to 6 months, although detailed long-term subgroup data were not announced. The therapy was generally well tolerated, with no reports of treatment-related serious adverse events.

Although SPL026 demonstrated proof-of-concept efficacy, Helus Pharma indicated it is not advancing the intravenous formulation in its current form. Instead, mechanistic and clinical insights from the trial are informing the development of HLP004, a proprietary novel serotonergic agonist under investigation for generalized anxiety disorder (GAD), with phase 2 topline data anticipated in the first quarter of 2026. The company is also advancing HLP003 in phase 3 development as adjunctive therapy for MDD; that program has received Breakthrough Therapy designation from the FDA.

“This publication represents an important validation of short-acting serotonergic agonists as a clinically meaningful approach in mental health treatments,” said Michael Cola, chief executive officer of Helus Pharma, in a statement. “The findings provide clinical proof-of-concept for short-acting serotonergic modulation and further support our conviction that our novel serotonergic agonist molecules, such as HLP004, can potentially deliver meaningful outcomes with greater consistency and commercial feasibility. We look forward to reporting topline data from our Phase 2 study of HLP004 in generalized anxiety disorder later this quarter.”

Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder. Helus Phama. Published on February 17, 2026. Accessed on February 19, 2026. 

https://www.globenewswire.com/news-release/2026/02/17/3239141/0/en/Nature-Medicine-Publishes-Helus-Pharma-s-Randomized-Placebo-Controlled-Phase-2a-Trial-of-SPL026-in-Major-Depressive-Disorder.html

Articles

A single 21.5-mg IV infusion of SPL026 (DMT) plus supportive psychotherapy produced a statistically significant and clinically meaningful MADRS reduction versus placebo in moderate-to-severe MDD, with separation by week 1 and sustained benefit at week 2. Acute psychoactive effects were brief (<30 minutes), supporting a shorter-session psychedelic model. In 34 participants, response and remission rates favored SPL026, and tolerability was acceptable without treatment-related serious adverse events. Despite proof-of-concept efficacy, development is shifting toward next-generation serotonergic agonists.

A phase 2a randomized, placebo-controlled study shows –7.35 MADRS difference at 2 weeks with SPL026 compared with placebo. However, the study is not advancing.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Intravenous DMT (SPL026) Demonstrates Significant MDD Reduction in Phase 2a Trial

Andres Hurtado-Lorenzo, PhD, is VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation.

Intermittent Fasting for Crohn’s Disease? New Clinical Trial Explained

Interest in dietary management of Crohn’s disease has long focused on identifying specific foods that trigger symptoms or promote remission, but a growing body of research is expanding that conversation beyond food composition alone. Increasingly, investigators are examining whether meal timing may influence inflammation, metabolic health, and the gut microbiome in patients with inflammatory bowel disease.

In a recent randomized clinical trial published in 

, researchers evaluated time-restricted feeding as a complementary strategy in adults with Crohn’s disease, adding new rigor to a field eager for validated lifestyle interventions.

In discussing the findings, Andres Hurtado-Lorenzo, PhD, VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation, emphasized that traditional dietary strategies in Crohn’s disease have largely focused on what patients should eat. While he says that food quality remains central, emerging science now suggests that when people eat may be equally important.

“Multiple studies in the context of other diseases have shown that meal timing can independently influence circadian regulated immune and metabolic pathways, microbial balance and adipose tissue biology, even without changes in calorie intake or nutrient composition,” Hurtado-Lorenzo explained. “In Crohn's disease, the intersection of chronic immune dysregulation, disturbances in gut microbiota, and high prevalence of overweight and obesity establishes a strong case for examining time based dietary interventions such as intermittent fasting.”

The 12-week randomized controlled trial evaluated the effects of a 16:8 time-restricted feeding protocol, in which participants fasted for 16 hours and consumed all meals within an 8-hour window. Investigators assessed the impact on clinical disease activity, body composition, and systemic inflammation in adults with Crohn’s in clinical remission and overweight or obesity.

Results showed that over 12 weeks, BMI decreased significantly in the time-restricted feeding group compared with controls (Δ –0.9 ± 0.03 kg/m2 vs +0.6 ± 0.3 kg/m2; 

 <.001). Energy intake and diet quality (Mediterranean Diet Index) did not differ between groups or across time, suggesting BMI reduction occurred independent of caloric restriction and diet quality.

Clinical disease activity as measured by the Harvey–Bradshaw Index also improved significantly in the time-restricted feeding group (Δ –2 ± 4 vs –0.5 ± 2; 

 = .02), with a 40% decrease in stool frequency and 50% reduction in abdominal discomfort, which was not observed in controls.

Additionally, compared with controls, the time-restricted feeding group exhibited significant reductions in serum adipokines, including leptin, plasminogen activator inhibitor-1, and adipsin (all, 

 < .05). Further analysis revealed ​​greater BMI loss correlated positively with both anti-inflammatory cytokines (interleukin [IL]1RA, IL4; 

 = 0.78) and pro-inflammatory cytokines (IL2, IL12p40, IL12p70; 

Hurtado-Lorenzo pointed to the magnitude and speed of change as being among the most striking findings from the study. From a mechanistic standpoint, he outlined 2 primary processes underlying these effects, metabolic remodeling and autophagy, and further hypothesized that fasting-induced autophagy could play a therapeutic role in Crohn’s due to its potential contribution to disease pathogenesis.

“Importantly, this is the first randomized clinical trial to demonstrate a benefit of intermittent fasting in patients with Crohn's disease, providing rigorous evidence in the field that is hungry for validated lifestyle strategies,” Hurtado-Lorenzo said. “In my opinion, this approach meets a real clinical need of sustaining remission by offering a practical solution in synergy with pharmacological treatment strategies for Crohn's disease.”

Crohn’s & Colitis Foundation of America. Intermittent fasting cut Crohn’s disease activity by 40% and halved inflammation in randomized clinical trial. February 9, 2026. Accessed February 19, 2026. 

https://www.eurekalert.org/news-releases/1114988

Haskey N, Ye J, Lewis A, Yousuf M, Reimer RA, Raman M. Time-Restricted Feeding Reduces Body Mass Index, Visceral Adiposity, Systemic Inflammation, and Clinical Disease Activity in Adults With Crohn's Disease: A Randomized Controlled Study. 

. Published online February 9, 2026. doi:10.1053/j.gastro.2025.11.008

Hurtado-Lorenzo explains the growing interest in meal timing as a potential lifestyle intervention for Crohn’s and recent trial data supporting its utility in this patient population.

Strategic Alliance Partnership

Meal Timing and Crohn’s Disease: Clinical Implications of Intermittent Fasting, With Andres Hurtado-Lorenzo, PhD

Janani Rangaswami, MD, FAHA, a nephrologist with expertise in cardiovascular- kidney medicine; Professor of Medicine, George Washington University, Washington DC; Co-chair, Scientific Advisory Group of the AHA's presidential advisory on CKM Health.

An estimated 90% of US adults fall somewhere along the cardiovascular-kidney-metabolic (CKM) spectrum, a framework clinicians are increasingly applying as new therapies, including GLP-1 receptor agonists for CKD, expand options for managing overlapping risk.

Introduced in a 2023 presidential advisory, the CKM model formalizes the interconnected relationship between cardiovascular disease, chronic kidney disease (CKD), obesity, diabetes, and metabolic dysfunction. Rather than viewing these conditions in isolation, the framework stages risk across a continuum from individuals without overt disease to those with advanced cardiovascular and kidney complications.

The framework has gained additional urgency as new therapies, including GLP-1 receptor agonists recently approved for CKD, provide clinicians with more tools to address overlapping metabolic and cardiorenal risk.

For Janani Rangaswami, MD, FAHA, professor of medicine at George Washington University and co-chair of the advisory’s scientific writing group, the shift reflects what clinicians are already seeing in daily practice.

In routine clinical practice, where do you most often see cardiovascular disease, CKD, and diabetes converge in the same patients, and how does that overlap influence management decisions?

So I think the overlap is so significant that after the framework of cardiovascular-kidney metabolic syndrome was put out by the American Heart Association — and I am co-chair of that scientific advisory group that wrote that presidential advisory in 2023 — the analysis of data in the United States shows that 90% of Americans are living with at least a stage of CKM syndrome. And you know, CKM syndrome encompasses the entire spectrum of risk, starting from people who have no risk factors or cardiovascular disease, going all the way through obesity, vascular risk factors, subclinical disease, and clinical cardiovascular disease.

And so in any healthcare setting — primary care, specialty care between cardiology, nephrology, and endocrinology — this is the bulk of practice. When you look at a specialty like in my practice, when I see individuals with kidney disease, diabetes alone is responsible for close to 50% of the cause behind that kidney disease. And then when you add in obesity and metabolic dysfunction and hypertension, all of these really come together very heavily. So that's why understanding that interconnectedness is so important between these three elements.

From a cardiorenal perspective, what did the approval of semaglutide in patients with CKD signal about how we are beginning to approach metabolic risk across both heart and kidney disease?

I think that was such an important development, because with the new therapies, and particularly with the GLPs, our approach to the management of kidney disease has evolved. When we didn't have some of these foundational classes — you know, the SGLT2 inhibitors came first, we have non-steroidal MRAs, and of course the incretin class therapies — a lot of the management of coexistent metabolic factors like diabetes or obesity was just like controlling A1c or counseling about weight management, and fully recognizing that obesity played such an important piece. But there were really no definitive therapies the way we have today.

Now, the standard of care across these foundational classes of therapies goes beyond just treating the risk factor. So while the GLPs in semaglutide are very effective for A1c management and weight management, the FLOW trial — which was the pivotal trial that led to the labeled approval of semaglutide in kidney disease with type 2 diabetes — showed that this therapy saved lives, hearts, and kidneys.

In patients with high and very high-risk kidney disease who are high risk for both kidney failure and cardiovascular events, there was consistent benefit seen for prevention of worsening kidney function needing dialysis and transplant. There was also consistent reduction in rates of cardiovascular adverse events, and there was a mortality benefit. So now these therapies do multiple things — they address everything from improving lifespan to improving health outcomes, heart and kidney, and then even beyond.

Because as we now know, semaglutide, apart from the weight loss perspective, also has liver benefits. So in metabolic liver disease, that's another area where you see another organ benefit. And we also know that in people without diabetes, in the SELECT trial, there is a primary cardiovascular benefit in non-diabetic but overweight or obese individuals. So truly, it's like a whole health approach. Even if the label is for kidney disease, we're benefiting all of these different aspects.

Given that cardiology is often the first specialty managing metabolic risk, how have you seen clinicians currently incorporating GLP-1 receptor agonists when kidney disease is also present?

Patients who may qualify for the kidney indication very likely also qualify for the other indications. If you look for the other indications, you will find them. It depends — sometimes patients in my practice have already been initiated, perhaps for weight management, or somebody has been screened for liver disease, and they have already been initiated on the therapy. Or sometimes I am the person initiating it for the kidney perspective.

We're also seeing that there's more liberal use now, with more access to therapy, so early on even if patients met the indication, access was a problem. Now we're seeing that improve, which is very reassuring. The nice thing about therapies like semaglutide is that there are multiple reasons, multiple clinical touch points, and multiple different types of clinicians who can initiate, and the benefits are still going to be accrued across multiple organ systems.

How do you clinically position GLP-1 receptor agonists alongside established therapies such as SGLT2 inhibitors and RAAS blockade in patients with both CKD and high cardiovascular risk?

 Not only do these therapies have multiple organ benefits, but patients with overlapping conditions, obesity, diabetes, kidney disease, and cardiovascular disease, will not just be eligible for one of these classes, but for multiple classes.

When you look at the design of the major trials that show these benefits, and the types of patients they included, there’s significant overlap. For example, in the FLOW trial, semaglutide was tested versus placebo on top of RAS inhibition and risk factor control. In the SGLT2 inhibitor trials, for the most part, that is true as well. There weren’t that many individuals in the GLP trials who were also on SGLT2 inhibitors, about 15%, but we know these therapies appear to be additive.

One plus one equals two. When we combine these therapies, we get the full benefit you would expect. In individuals at the very high end of the spectrum of risk, whether from a cardiovascular or kidney perspective, they are eligible for multiple therapies because they will still have adverse outcomes if left on just one class. This opens the discussion for a whole new era for the concept of combination therapies across multiple foundational classes, RAAS inhibition, GLPs, SGLT2 inhibitors, and non-steroidal MRAs, especially in type 2 diabetes plus kidney disease, all of which have high-level evidence for benefit.

Editor’s Note: Rangaswami reports relevant disclosures with the American Heart Association.

Chang R, Parekh T, Hagan KK, Javed Z, Ostrominski JW. State-Level Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in the United States, 2011 to 2023. 

https://doi.org/10.1016/j.jacadv.2025.101754

National Kidney Foundation. FDA Approves Ozempic for Type 2 Diabetes and Chronic Kidney Disease. National Kidney Foundation. Published February 20, 2025. 

https://www.kidney.org/news-stories/fda-approves-ozempic-type-2-diabetes-and-chronic-kidney-disease

An estimated 90% of US adults fall along the cardiovascular-kidney-metabolic (CKM) continuum, reflecting pervasive overlap among obesity, diabetes, CKD, and cardiovascular disease. The CKM framework, introduced by the AHA in 2023, stages risk from no overt disease to advanced cardiorenal complications and supports integrated management across specialties. Semaglutide’s CKD indication, supported by FLOW, signals a shift from risk-factor control toward therapies delivering kidney, cardiovascular, and mortality benefits, with additional hepatic and non-diabetic cardiovascular advantages.

CKM syndrome affects nearly 90% of US adults, highlighting the need to manage cardiovascular, kidney, and metabolic risk together.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Why Cardiovascular, Kidney, Metabolic Risk Must Be Managed Together, With Janani Rangaswami, MD, FAHA

Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers a new mechanistic approach in kidney transplant care.

Mechanistic Rationale for Dual Costimulation Blockade, Belatacept, Dazodalibep in Kidney Transplantation

Ahmad Anouti, MD, is a pediatric resident at the University of Texas Southwestern in the Physician Scientist Training Program.

Anouti outlines why early bilirubin testing and emerging serum markers are key to improving prognosis in biliary atresia.

Hepatology

Advancing Prognostic Tools in Biliary Atresia Care, With Ahmad Anouti, MD

Nina Ajmone Marsan, MD, is a research fellow in the department of cardiology at Leiden University Medical Center.

Marsan and Santi discuss their recent study highlighting the need for lower LVESVi thresholds in aortic valve surgery in women to reduce mortality outcomes.

Female Patients With AR Exhibit Lower Mortality LVESVi Thresholds, With Nina Marsan, MD, and Pilar Santi, MD

A large specialty pharmacy cohort supports sustained reductions in attack rates across HAE subtypes, including normal C1 inhibitor disease.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Real-World HAE Control with Berotralstat at 18 Months, With Raffi Tachdjian, MD

Updated international guidance reinforces early self-administered on-demand therapy and integrates newer kallikrein-targeted agents into routine HAE management.


Pediatric HAE Guideline Recommends Sebetralstat as First-Line Therapy

Alan Buchman MD, MSPH, is a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health.

New data show limited uptake of SBS-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease.

ICD-10 Adoption and the True Burden of Short Bowel Syndrome, With Alan Buchman, MD, MSPH

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

These retrospective cohort studies also showed the vaccine’s reduction of heart attack, stroke, and asthma/COPD flare-ups in patients with RSV.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSV

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These data, released by Lilly, suggest ixekizumab (Taltz) and tirzepatide (Zepbound) are more effective when used together versus ixekizumab monotherapy.

Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight

Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.

Dyslipidemia

CORALreef Lipids: Enlicitide Reduces LDL-C in Patients With ASCVD, With Ann Marie Navar, MD, PhD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Latest News

3-Year Patient-Reported Psoriasis Outcomes for Bimekizumab, With Ron Vender, MD

PROFUNDUS: Real-World Outcomes With Upadacitinib in Ulcerative Colitis, With Remo Panaccione, MD

Intravenous DMT (SPL026) Demonstrates Significant MDD Reduction in Phase 2a Trial

Meal Timing and Crohn’s Disease: Clinical Implications of Intermittent Fasting, With Andres Hurtado-Lorenzo, PhD

Why Cardiovascular, Kidney, Metabolic Risk Must Be Managed Together, With Janani Rangaswami, MD, FAHA